Treace Q2 2026 Earnings: Cost Cuts Narrow Loss Despite Lower Revenue

Treace Medical Concepts (NASDAQ: TMCI) reported Q2 2026 revenue of $45.4 million, down 4% from $47.4 million a year earlier, while GAAP diluted loss per share narrowed to $0.24 from $0.28 for the quarter ended June 30. Targeted cost reductions pushed operating expenses down 8% and narrowed the net loss, although gross margin fell to 78.5% and adjusted EBITDA remained negative at $3.5 million. Treace also raised the low end of its full-year revenue range and improved its adjusted EBITDA outlook.

Core earnings data

Revenue decreased by approximately $2.0 million year over year, while gross profit fell by about $2.1 million as cost of goods sold edged higher. Gross margin consequently declined by 1.2 percentage points to 78.5%.

Expense reductions were large enough to offset the lower gross profit. Total operating expenses fell by approximately $4.2 million, allowing the operating loss to narrow by about $2.0 million and the net loss to improve by $1.5 million.

Adjusted EBITDA is a non-GAAP measure that excludes items including share-based compensation, litigation costs, interest, and depreciation and amortization.

Business and portfolio performance

Treace’s operational update focused on adoption rather than revenue by product. Approximately 40% of Lapiplasty surgeon users had incorporated at least one of the three new bunion systems introduced in Q3 2025, up from 35% in Q1 2026. That represents a five-percentage-point sequential increase in adoption.

The company also began a limited market release of its SuperBite Compression Screw System and completed the first surgical case using the HyperPlate XM Dynamic Compression Locking Implant System. These products broaden Treace’s coverage of foot and ankle procedures, but the company did not disclose their revenue contribution.

Management attributed the improving year-over-year case-volume trend and market-share gains to greater adoption of the broader bunion portfolio and newer technologies. Revenue nevertheless remained below the prior-year level, making conversion of adoption into sales growth an important second-half measure.

Profitability, cash flow, and balance sheet

Expense reductions offset lower gross profit

The operating-expense decline was broad. Sales and marketing expense fell to $30.9 million from $33.1 million, research and development expense decreased to $4.4 million from $5.5 million, and general and administrative expense declined to $15.2 million from $16.1 million. Treace attributed the overall reduction to targeted expense initiatives across the organization.

The benefit was partly offset by weaker gross-margin performance. Cost of goods sold increased slightly to $9.8 million even though revenue declined, causing gross profit to fall faster than sales.

Working capital supported year-to-date cash flow

Cash-flow figures cover the six months ended June 30 rather than Q2 alone. Operating activities generated $2.5 million of cash, compared with $1.1 million in the first half of 2025, despite a year-to-date GAAP net loss of $33.8 million.

The difference was supported by $14.5 million of non-cash share-based compensation and working-capital movements, including a $13.2 million reduction in accounts receivable and a $9.3 million increase in accounts payable. Inventory growth used $3.5 million of cash. Treace separately reported that year-to-date cash usage declined by 57%, or $3.6 million, from the prior-year period.

Cash and cash equivalents totaled $12.6 million, while marketable securities were $33.0 million, providing combined cash and securities of $45.6 million at June 30. Net long-term debt was $56.0 million. The company said its credit facility could provide an additional $115 million of liquidity, subject to certain conditions.

2026 financial guidance

Treace raised the lower end of its full-year revenue guidance by $2 million while leaving the upper end unchanged. It also improved both ends of its expected adjusted EBITDA loss range by $1 million and reiterated its cash-usage target.

The revenue range represents a year-over-year change of negative 4% to flat. The outlook assumes continued case-volume growth and better year-over-year growth rates in the second half as previously identified headwinds are annualized.

Risks investors should monitor

• The revenue recovery remains incomplete. Q2 revenue declined 4%, and full-year guidance still allows for a decline of as much as 4%. The outlook depends on continued case-volume growth and improving second-half comparisons.
• Gross-margin pressure could delay profitability. Gross margin fell from 79.7% to 78.5%, with cost of goods sold increasing slightly despite lower revenue.
• Losses and liquidity requirements remain material. Treace recorded a $15.9 million quarterly net loss and negative adjusted EBITDA, while its additional credit-facility liquidity remains subject to conditions.
• Competition and elective-procedure demand may affect growth. The company identified increased competition, changing preferences for minimally invasive bunion procedures, and weaker elective-surgery demand amid macroeconomic uncertainty as potential headwinds.
• Intellectual-property litigation costs increased. Quarterly litigation costs rose to $2.1 million from $1.1 million, while first-half costs increased to $4.3 million from $1.5 million.

Summary

Treace’s Q2 2026 results showed better cost control rather than a return to revenue growth. Expense reductions more than offset the decline in gross profit, narrowing the GAAP loss, while working-capital movements supported positive first-half operating cash flow. Management is relying on broader product adoption and continued case-volume growth to improve second-half comparisons, but revenue contraction, lower gross margin, and negative adjusted EBITDA remain the main financial indicators to monitor.